Agilisium
Regulatory Content WorkspacePowered by Agilisium

Welcome, Sarah

Your assigned regulatory content across active submissions.

Product X  ·  EU MAA
Module 2.5 — Clinical Overview
Section of the Clinical Overview requires first draft
Status
Draft Required
Due
15 Oct 2026
Priority
High
Product X  ·  US NDA
Module 2.7 — Clinical Summary
Reviewer comments pending your response
Status
In Review
Due
02 Nov 2026
Priority
Medium
Product Y  ·  Variation
Safety Update — Periodic Report
Approved and handed off to Regulatory Operations
Status
Complete
Due
28 Aug 2026
Priority
Low

Module 2.7 — Clinical Summary

Product X — US NDA  ·  submission workspace

In Review
Product
Product X
Submission Type
NDA
Region
US
Health Authority
FDA
Due
02 Nov 2026
Reviewer
Dr. A. Whitfield
Author
Sarah Klein
Version
v0.6 Draft

Open Reviewer Comments

3 pending your response
2.7.3 Summary of Clinical Efficacy — clarify pooled analysis populationOpen
2.7.4 Summary of Clinical Safety — align AE coding to latest MedDRA versionOpen
2.7.6 Synopses — add cross-reference to CSR-302Open

Safety Update — Periodic Report

Product Y — Type II Variation  ·  completed assignment

Complete
Product
Product Y
Submission Type
Type II Variation
Region
EU
Health Authority
EMA
Approved
28 Aug 2026
Approver
M. Okafor
Author
Sarah Klein
Version
v2.0 Final

Completion Record

Read-only — handed off to Regulatory Operations
✓ Regulatory QC passed — no open findings
✓ Clinical, Safety and Regulatory reviews signed off
✓ Approved version archived with full evidence traceability
✓ Handed off to Regulatory Operations for dispatch

Product X — EU MAA

Marketing Authorisation Application submission workspace

Submission Readiness
62%
Product
Product X
Indication
Indication B
Submission Type
MAA
Region
EU
Health Authority
EMA
Target Date
15 Oct 2026
Regulatory Lead
M. Okafor
Medical Writing Lead
Sarah Klein

eCTD Content Plan

Veeva Vault RIM — System of Record
▸ Module 1 — Administrative & Prescribing Information
80%
Regional administrative documentsOn Track
▸ Module 2 — Common Technical Document Summaries
55%
2.3 Quality Overall SummaryComplete
2.4 Nonclinical OverviewComplete
2.5 Clinical Overview  — assigned to meDraft Required
2.6 Nonclinical SummaryIn Review
2.7 Clinical SummaryDrafting
▸ Module 3 — Quality
75%
CMC documentation setIn Progress
▸ Module 4 — Nonclinical Study Reports
90%
Nonclinical study report setOn Track
▸ Module 5 — Clinical Study Reports
70%
CSR PX-301 and supporting TLFsIn Progress

Module 2.5 — Clinical Overview

Document details and authoring readiness

Draft Required

Document Metadata

Owner
Sarah Klein
Due Date
15 Oct 2026
Template
Approved EU MAA Clinical Overview
Current Version
0.1 (Not started)
Submission
Product X — EU MAA
Product / Indication
Product X / Indication B

Authoring Readiness

✓ Approved template available
✓ Product metadata available
✓ Current Protocol available (PX-301)
✓ CSR available (PX-301, v3.0)
✓ Efficacy evidence available
✓ Safety evidence available
✓ Previous approved submissions found (2)

All prerequisites are in place. Start authoring with the Regulatory AI Assistant, or review source evidence first.

Module 2.5 — Clinical Overview

AI-assisted authoring workspace

Draft Required
Document Structure
Product Development Rationale
Section 1 of 6
Regulatory AI Assistant
Operating Context
Product X Indication B EU MAA Module 2.5
AI proposes actions and drafts. Sarah accepts, modifies or rejects every recommendation — nothing is auto-approved.

Reusable Content Recommendations

Approved content identified across Product X submissions with evidence-linked provenance

Candidate 1 — Clinical Pharmacology
Product X — US NDA  ·  Module 2.5.3 Clinical Pharmacology  ·  Approved
Context Match
91% · High
Same
✓ Product
✓ Formulation
✓ Dose
Different
⚠ Indication
⚠ Patient Population
AI Recommendation
REUSE WITH MODIFICATION
Candidate 2 — Safety Overview
Product X — Previous EU Submission (Type II Variation)  ·  Approved
Context Match
76% · Medium
Differences Detected
⚠ New Safety Data Cut
⚠ Additional 486 Subjects
AI Recommendation
UPDATE REQUIRED

Regulatory Context Comparison

Candidate 1 — Clinical Pharmacology (Product X — US NDA)

Current Context
Product
Product X
Product
Product X
Indication
Indication A
Indication
Indication B
Population
Adult
Population
Adult
Dose
100 mg
Dose
100 mg
Data Cut
2024
Data Cut
2026
Subjects
820
Subjects
1,306
Market
US
Market
EU
Submission
NDA
Submission
MAA
REUSE WITH MODIFICATION

"Core product, formulation and dose context remains applicable. Efficacy and safety statements require updating because indication and data cut have changed."

Regulatory Context Comparison

Candidate 2 — Safety Overview (Product X — Previous EU Submission)

Current Context
Product
Product X
Product
Product X
Indication
Indication B
Indication
Indication B
Dose
100 mg
Dose
100 mg
Data Cut
2025
Data Cut
2026
Subjects
820
Subjects
1,306  (+486)
Market
EU
Market
EU
Submission
Type II Variation
Submission
MAA
UPDATE REQUIRED

"Safety population has grown by 486 subjects under a newer data cut. Exposure and adverse-event summaries must be refreshed before this content can be reused."

Regulatory QC

Module 2.5 — Clinical Overview  ·  Automated quality and consistency checks

92%
QC Score
✓ Approved template used
✓ Current product terminology
✓ Current indication (Indication B)
✓ Evidence traceability
✓ No superseded content detected
✓ Required sections complete
! 2 numerical values require verification, 1 cross-document inconsistency

Issues to Resolve

3 open

Content Ready for Review

Module 2.5 — Clinical Overview

Readiness Checklist

✓ Content completed
✓ Evidence verified
✓ Reuse provenance captured
✓ QC completed — score 100%
✓ No critical issues

Review Workflow

Every reviewer sees the same evidence-linked content Sarah authored. Nothing is approved automatically.

Reviewer Feedback

Module 2.5 — Clinical Overview  ·  In Review

CR Clinical Reviewer
Open

"Please confirm the efficacy population used in Section 4 — the responder rate should be verified against the CSR primary analysis population."

SR Safety Reviewer
Open

"Update safety exposure narrative in Section 5 using the latest approved data cut — current text still references the interim 24-week follow-up."

Module 2.5 Clinical Overview

Medical writing activities complete

Approved

Approval Details

Version
1.0 — Final
Approval Date
14 Oct 2026
Approved By
M. Okafor, Regulatory Lead
Submission Content Plan
Complete
✓ Evidence traceability complete
✓ QC passed — score 100%
✓ Clinical, Safety & Regulatory review complete

What Happens Next

Approved Content
→
Submission Content Plan
→
eCTD Publishing
→
Technical Validation
→
Submission Package

Sarah's role on Module 2.5 is complete. Technical eCTD publishing is performed by Regulatory Operations, not the Medical Writer.

Product X — EU MAA Submission Readiness

Responsibility has transitioned to Regulatory Operations for eCTD publishing

Overall Readiness
96%
MODULE 1
100%
Complete
MODULE 2
100%
Complete
MODULE 3
95%
Near Complete
MODULE 4
100%
Complete
MODULE 5
92%
Near Complete

Remaining Dependencies

Owned by Regulatory Operations
Module 3 — 1 document awaiting final approvalAt Risk
Module 5 — 2 hyperlinks awaiting publishing QCAt Risk
Medical Writing complete. Regulatory Operations now owns eCTD technical publishing and submission dispatch to EMA.
✓
Demo Guide
Step 1 of 11
—

—

Try this next—